Benzene exposure and refractory sideroblastic erythropoiesis: Is there an association?

American Journal of the Medical Sciences

Volumn 334, Issue 5, 2007, Pages 356-360

  Natelson, Ethan A ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b Smith Towers   (United States)

Author keywords

Benzene; MDS; Myelodysplasia; Refractory Sideroblastic Anemia

Indexed keywords

BENZENE;

ACUTE GRANULOCYTIC LEUKEMIA; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ENVIRONMENT; ENVIRONMENTAL FACTOR; EXPOSURE; HEMATOLOGIC MALIGNANCY; HUMAN; MYELODYSPLASTIC SYNDROME; REFRACTORY ANEMIA; REFRACTORY SIDEROBLASTIC ERYTHROPOIESIS; REVIEW; RISK FACTOR; TOXICITY; CHEMICALLY INDUCED DISORDER; ERYTHROPOIESIS; PATHOPHYSIOLOGY; PHYSIOLOGY; POLLUTANT; SIDEROBLASTIC ANEMIA;

ANEMIA, SIDEROBLASTIC; BENZENE; ENVIRONMENTAL POLLUTANTS; ERYTHROPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; RISK FACTORS;

EID: 38449122981     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3180cab70a     Document Type: Review

References (59)

1. Catenacci D.V.T. Schiller G.J. Myelodysplasic (sic) syndromes: a comprehensive review Blood Rev 19 2005 301 319
2. Kantarjian H. Myelodysplastic syndromes (MDS): what is new? Leukemia Insights 11 2006 1 7
3. Aul C. Bowen D.T. Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes Haematol 83 1998 71 86
4. Cazzola M. Malcovati I. Myelodysplastic syndromes: coping with ineffective hematopoiesis N Engl J Med 352 2005 536 538
5. Heaney M. Golde D.W. Myelodysplasia N Engl J Med 340 1999 1649 1660
6. Breccia M. Mengarelli A. Mancini M. Myelodysplastic syndromes in patients under 50 years old: a single institution experience Leuk Res 29 2005 749 754
7. Strom S.S. Gu Y. Gruschkus S.K. EH Risk factors of myelodysplastic syndrome: a case control study Leukemia 19 2005 1912 1918
8. Hayes R.B. Yin S.-N. Dosemici M. Benzene and the dose-related incidence of hematologic neoplasms in China J Natl Cancer Inst 89 1997 1065 1071
9. Estey E. Döhner H. Acute myeloid leukaemia Lancet 368 2006 1894 1907
10. Malcovati L. Della Porta M.G. Pascutto C. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 2005 7594 7603
11. Müller-Berndorff H. Haas P.S. Kunzmann R. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis Ann Hematol 85 2006 502 513
12. Kushner J.P. Lee G.R. Wintrobe M.M. Idiopathic refractory sideroblastic anemia: clinical and laboratory investigation of 17 patients and review of the literature Medicine 50 1971 139 159
13. Cheng D.S. Kushner J.P. Wintrobe M.M. Idiopathic refractory sideroblastic anemia: incidence and risk factors for leukemic transformation Cancer 44 1979 724 751
14. Cazzola M. Barosi G. Gobbi P.G. Natural history of idiopathic refractory sideroblastic anemia Blood 71 1988 305 312
15. Dameshek W. Sideroblastic anaemia: is this a malignancy? Br J Haematol 11 1965 52 58
16. Beutler E. Robson M.J. Buttenwieser B. A comparison of the plasma iron, iron-binding capacity, sternal marrow iron and other methods in the clinical evaluation of iron stores Ann Intern Med 48 1958 60 82
17. Kuendgen A. Strupp C. Aivado M. Myelodysplastic syndromes in patients younger than age 50 J Clin Oncol 24 2006 5358 5365
18. Vandermolen L. Rice L. Rose M.A. Ringed sideroblasts in primary myelodysplasia: leukemic propensity and prognostic factors Ann Intern Med 148 1988 653 656
19. Garand R. Gardais J. Bizet M. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA) Leukemia Res 16 1992 463 468
20. Germing U. Gattermann N. Arvedo M. Two types of acquired idiopathic sideroblastic anaemia (AlSA): a time tested distinction Br J Haematol 108 2000 724 728
21. Schwartz S. Jiji R. Meekins J. Chromosome abnormalities in acquired idiopathic sideroblastic anemia with subsequent leukemic transformation Can Gen Cytogenet 19 1986 291 299
22. Olney H.J. Le Beau M.M. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes Leuk Res 31 2007 427 434
23. Kurtin P.J. Dewald G.W. Shields D.J. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients Am J Clin Pathol 106 1996 680 688
24. Cabello A.I. Collado R. Ruiz M.Á. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals Leuk Res 29 2005 365 370
25. Shaw G.R. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults Br J Haematol 31 2005 180 184
26. Szpurka R. Tiu G. Murugesan S. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation Blood 2006 2173 2181
27. Boissinot M. Garand R. Hamidou M. The JAK2-V61F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS) Blood 108 2006 1781 1782
28. Villeval J.-L. James C. Pisani D.F. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients Semin Thromb Haemost 32 2006 341 351
29. Scully R.E. Mark E.J. McNeely W.F. BU Weekly Clinicopathologial Exercises (case 17-1992) N Engl J Med 326 1992 1137 1146
30. Malcovati L. Germing U. Kuendgen A. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 2007 3503 3510
31. Zervas J. Geary C.G. Oleesky S. Sideroblastic anemia treated with immunosuppressive therapy Blood 44 1974 117 123
32. Lin J.-T. Wang W.-S. Yen C.-C. Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil Ann Hematol 81 2002 723 726
33. Natelson E. Pregnancy-induced pancytopenia: distinctive hematological features Am J Med Sci 332 2006 205 207
34. Huff J.D. Keung Y. Thakuri M. Copper deficiency causes reversible myelodysplasia Am J Hematol 82 2007 advance e-publication
35. Kitahara M. Cosgriff T.M. Eyre H.J. Sideroblastic Anemia as a preleukemic event in patients treated for Hodgkin’s disease Ann Intern Med 92 1980 625 627
36. Magalhães S.M.M. Durate F.B. Ribeiro S.C.C. Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan Leukemia 14 2002 214 215
37. Fernandez L.A. Zayed E. Busulfan-induced sideroblastic anemia Am J Hematol 28 1998 199 200
38. Linet M.S. Yin S.-N. Travis L.B. Clinical features of hematopoietic malignancies and related disorders among benzene exposed workers in china Environ Health Perspect 104 1996 1353 1364
39. Aksoy M. Different types of malignancies due to occupational exposure to benzene: a review of recent observations in Turkey Environ Res 23 1980 181 190
40. Aksoy M. Dinçol K. Akgün T. Haematological effects of chronic benzene poisoning in 217 workers Br J Indust Med 28 1971 296 302
41. Rinsky R.A. Hornung R.W. Silver S.R. Benzene exposure and hematopoietic mortality: a long-term epidemiologic risk assessment Am J Indust Med 42 2002 474 480
42. Irons R.D. Lv L. Gross S.A. Chronic exposure to benzene results in a unique form of dysplasia Leukemia Res 29 2005 1371 1380
43. Ruiz M.A. Augusto L.G.S. Vassallo J. Bone marrow morphology in patients with neutropenia due to chronic exposure to organic solvents (benzene): early lesions Path Res Pract 190 1994 151 154
44. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes and myelodysplastic/myeloproliferative diseases Pathobid 74 2007 97 114
45. Björk J. Albin M. Mauritzson N. Smoking and myelodysplastic syndromes Epidemiol 11 2000 285 291
46. Pasqualetti P. Festucia V. Acitelli P. Tobacco smoking and risk of haematological malignancies in adults: a case-control study Br J Haematol 97 1997 659 662
47. Carmona R. The Surgeon General’s 2004 report, The Health Consequences of Smoking. US Dept Health and Human Services, Chap 2, p 254
48. Chelghoum Y. Danaïla C. Belhabri A. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia Ann Oncol 13 2002 1621 1627
49. Lichtman M.A. Cigarette smoking, cytogenetic abnormalities, and acute myelogenous leukemia Leuk 21 2007 1137 1140
50. Thomas X. Chelghoum Y. Cigarette smoking and acute leukemia Leuk Lymphoma 45 2004 1103 1109
51. Kane E.V. Roman E. Cartwright R. Tobacco and the risk of acute leukaemia in adults Br J Cancer 81 1999 1228 1233
52. Davico L. Sacerdote C. Ciccone G. Chromosome 8, occupational exposures, smoking, and acute nonlymphocytic leukemias: a population-based study Can Epidemiol Biomarkers Prev 7 1998 1123 1125
53. Moorman A.V. Roman E. Cartwright R.A. Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups Br J Cancer 86 2002 60 62
54. Smith M.A. McCaffrey R.P. Karp J.E. The secondary leukemias: challenges and research directions J Natl Cancer Inst 88 1996 407 418
55. Morgan G.J. Alvares C.L. Benzene and the hematopoietic stem cell Chemico-Biol Interact 153-154 2005 217 222
56. Yoshida Y. Oguma S. Tohyama K. Diagnostic and biological significance of sideroblastic erythropoiesis in the myelodysplastic syndromes Int J Hematol 67 1998 137 144
57. List A. Kurtin S. Roe D.J. Efficacy of Lenalidomide in myelodysplastic syndromes N Engl J Med 352 2005 549 557
58. Alexander D.D. Mink P.J. Adami H.O. The non-Hodgkin lymphomas: A review of the epidemiologic literature Int J Can 120 2007 1 39
59. Wang S.S. Slager S.L. Brennan P. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10211 cases and 11905 controls from the International Lymphoma Epidemiology Consortium (InterLymph) Blood 109 2007 3479 3488